Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QH104 Cell Injection for Meningeal Metastases of B7H3+ Solid Tumors
NCT06592092Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2024
- Primary completion
- May 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Open-label, single-arm trial of QH104 in leptomeningeal metastasis (LMD) and solid tumor, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Clinical response at 14 days. Started Apr 2024; status: completed.
02
Drugs
QH104
03
Conditions
leptomeningeal metastasis (LMD)solid tumor
Beyond the preview
Go deeper on NCT06592092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06592092.